A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT02809053 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Follicular

Interventions

BIOLOGICAL: SAIT101
BIOLOGICAL: MabThera®

Sponsor

Archigen Biotech Limited